Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants
| dc.contributor.author | Cooper, Curtis L | |
| dc.contributor.author | Read, Daniel | |
| dc.contributor.author | Vachon, Marie-Louise | |
| dc.contributor.author | Conway, Brian | |
| dc.contributor.author | Wong, Alexander | |
| dc.contributor.author | Ramji, Alnoor | |
| dc.contributor.author | Borgia, Sergio | |
| dc.contributor.author | Tam, Ed | |
| dc.contributor.author | Barrett, Lisa | |
| dc.contributor.author | Smyth, Dan | |
| dc.contributor.author | Feld, Jordan J | |
| dc.contributor.author | Lee, Sam | |
| dc.date.accessioned | 2020-09-06T00:09:16Z | |
| dc.date.available | 2020-09-06T00:09:16Z | |
| dc.date.issued | 2020-09-03 | |
| dc.date.updated | 2020-09-06T00:09:16Z | |
| dc.description.abstract | Abstract Background There are multiple obstacles encountered by immigrants attempting to engage hepatitis C virus (HCV) care and treatment. We evaluated the diversity and treatment outcomes of HCV-infected immigrants evaluated for Direct Acting Antiviral (DAA) therapy in Canada. Methods The Canadian Network Undertaking against Hepatitis C (CANUHC) Cohort contains demographic information and DAA treatment information prospectively collected at 10 Canadian sites. Information on country of origin and race are collected. Characteristics and outcomes (sustained virological response; SVR) were compared by immigration status and race. Results Between January 2016 and May 2018, 725 HCV-infected patients assessed for DAA therapy were enrolled in CANUHC (mean age: 52.66 ± 12.68 years); 65.66% male; 82.08% White, 5.28% Indigenous, 4.64% South East Asian, 4.64% East Indian, 3.36% Black). 18.48% were born outside of Canada. Mean age was similar [immigrants: 54.36 ± 13.95 years), Canadian-born: 52.27 ± 12.35 years); (p = 0.085)]. The overall baseline fibrosis score (in kPa measured by transient elastography) was similar among Canadian and foreign-born patients. Fibrosis score was not predicted by race or genotype. The proportion initiating DAA therapy was similar by immigrant status (56.72% vs 49.92%). SVR rates by intent-to-treat analysis were similar (immigrants-89.47%, Canadian-born-92.52%; p = 0.575). Conclusion A diverse immigrant population is engaging care in Canada, initiating HCV antiviral therapy in an equitable fashion and achieving SVR proportions similar to Canada-born patients. Our Canadian experience may be of value in informing HCV elimination efforts in economically developed regions. | |
| dc.identifier.citation | BMC Public Health. 2020 Sep 03;20(1):1345 | |
| dc.identifier.doi | https://doi.org/10.1186/s12889-020-09464-0 | |
| dc.identifier.uri | http://hdl.handle.net/1880/112497 | |
| dc.identifier.uri | https://doi.org/10.11575/PRISM/45369 | |
| dc.language.rfc3066 | en | |
| dc.rights.holder | The Author(s) | |
| dc.title | Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants | |
| dc.type | Journal Article |